PolyPid schedules Type D meeting with FDA on SHIELD 1 Phase 3 results
The Fly

PolyPid schedules Type D meeting with FDA on SHIELD 1 Phase 3 results

PolyPid announced that a Type D meeting has been scheduled for January 2023 with the U.S. Food and Drug Administration to discuss the results of SHIELD I Phase 3 study and regulatory requirements to support the indication of D-PLEX100 for the prevention of abdominal colorectal surgical site infections. In advance of the meeting, PolyPid recently provided the FDA with currently available data from the completed SHIELD I study.

Published first on TheFly

See the top stocks recommended by analysts >>

Read More on PYPD:

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App